Justin Meng Ko, MD

Offices

3 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

9 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ko’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026

California Medical Board record

Licence A120641 · Current

Licensed to practise in California · since 2012 · expires 2027-07-31 · Tufts University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$24,676

Medicare paid this office $24,676 for 111 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Return visit (30+ min)	36	$3,525	$82
Short return visit (20+ min)	24	$1,505	$52
Destruction of precancer skin growth, 1 growth	19	$1,172	$45
Biopsy of related skin growth, first growth	12	$358	$30
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	12	$178	$14

See all 6 services

Sort by

Every Original Medicare service billed

Return visit (30+ min)	36	$3,525	$82
Short return visit (20+ min)	24	$1,505	$52
Destruction of precancer skin growth, 1 growth	19	$1,172	$45
Biopsy of related skin growth, first growth	12	$358	$30
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	12	$178	$14
Destruction of precancer skin growth, 2-14 growths	13	$154	$2

Procedures Medicare counted

Sort by

Procedure volume Medicare published

Removal of skin lesions	95	More than 75% of doctors who do this
Removal or shaving of skin growth	1-10	None
Skin biopsy	17	More than 62% of doctors who do this

Who their Medicare patients are

111 Original Medicare patients in 2024. Average age 75 · Women 50% · Also on Medicaid 11% · Health risk score 1.11. Above the middle of the specialty; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 55% · Cancer 20% · Coronary heart disease 19% · Diabetes 16% · Chronic kidney disease 16% · Depression 14% · Heart failure 11% · Atrial fibrillation 10%.

The office billed $112,015, Medicare allowed $32,901 and paid $24,676; for 492 services of 26 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	111	492	75	1.11	$112,015	$24,676
2023	81	277	74	1.18	$48,516	$13,545
2022	76	266	76	0.94	$50,244	$13,629
2021	45	188	76	1.13	$30,098	$8,146
2020	167	387	73	1.28	$75,947	$15,575
2019	151	693	73	1.23	$143,769	$28,240
2018	176	845	72	1.27	$139,726	$31,393
2017	252	1,318	72	1.14	$284,584	$45,386
2016	307	1,651	73	1.24	$292,679	$49,181
2015	416	2,259	73	1.23	$409,683	$72,070
2014	452	1,680	72	1.14	$290,392	$66,968
2013	326	1,074	70	1.13	$206,382	$45,298

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 4 services

Sort by

Original Medicare services billed in 2023

Return visit (30+ min)	19	$1,510	$79
Return visit (30+ min)	13	$1,174	$84
Destruction of precancer skin growth, 1 growth	11	$682	$49
Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes	19	$525	$28

2022: 3 services

Sort by

Original Medicare services billed in 2022

Return visit (30+ min)	18	$2,126	$82
Short return visit (20+ min)	16	$1,056	$53
Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes	19	$583	$31

2021: 1 service

Sort by

Original Medicare services billed in 2021

Return visit (30+ min)	15	$1,087	$68

2020: 5 services

Sort by

Original Medicare services billed in 2020

Return visit (30+ min)	35	$2,514	$63
Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes	72	$1,978	$27
Short return visit (20+ min)	32	$1,526	$40
Destruction of precancer skin growth, 1 growth	16	$640	$36
Destruction of precancer skin growth, 2-14 growths	12	$115	$2

2019: 7 services

Sort by

Original Medicare services billed in 2019

Short return visit (20+ min)	68	$3,454	$40
Return visit (30+ min)	47	$3,296	$65
Destruction of precancer skin growth, 1 growth	36	$2,248	$42
Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes	32	$1,062	$33
Destruction of skin growth, 1-14 growths	15	$1,007	$56
Destruction of precancer skin growth, 2-14 growths	29	$408	$2
Biopsy of related skin growth, first growth	13	$290	$19

2018: 8 services

Sort by

Original Medicare services billed in 2018

Return visit (30+ min)	58	$5,917	$64
Short return visit (20+ min)	87	$4,437	$37
Destruction of precancer skin growth, 1 growth	53	$2,773	$36
Destruction of skin growth, 1-14 growths	22	$1,868	$57
Biopsy of single growth of skin and/or tissue	37	$1,395	$35
Return visit (30+ min)	16	$1,201	$71
New patient visit (30+ min)	16	$898	$56
Destruction of precancer skin growth, 2-14 growths	44	$480	$2

2017: 9 services

Sort by

Original Medicare services billed in 2017

Short return visit (20+ min)	140	$7,613	$40
Return visit (30+ min)	68	$6,016	$61
Destruction of precancer skin growth, 1 growth	78	$4,465	$40
Destruction of skin growth, 1-14 growths	32	$2,622	$62
New patient visit (30+ min)	33	$1,869	$57
Return visit (30+ min)	15	$1,552	$71
Biopsy of single growth of skin and/or tissue	39	$1,234	$26
Destruction of precancer skin growth, 2-14 growths	61	$946	$2
Biopsy of each additional growth of skin and/or tissue	11	$407	$23

2016: 8 services

Sort by

Original Medicare services billed in 2016

Short return visit (20+ min)	183	$10,730	$42
Return visit (30+ min)	76	$7,246	$65
Destruction of precancer skin growth, 1 growth	99	$6,437	$42
Destruction of skin growth, 1-14 growths	42	$3,251	$66
New patient visit (30+ min)	40	$2,416	$60
Biopsy of single growth of skin and/or tissue	57	$1,884	$30
Return visit (30+ min)	16	$1,471	$70
Destruction of precancer skin growth, 2-14 growths	82	$1,465	$2

2015: 12 services

Sort by

Original Medicare services billed in 2015

Short return visit (20+ min)	243	$14,611	$41
Return visit (30+ min)	113	$11,825	$66
Destruction of precancer skin growth, 1 growth	126	$8,197	$43
New patient visit (30+ min)	70	$4,057	$58
Destruction of skin growth, 1-14 growths	52	$3,631	$62
Biopsy of single growth of skin and/or tissue	70	$2,602	$32
Destruction of precancer skin growth, 2-14 growths	105	$1,880	$2
New patient visit (15+ min)	22	$842	$38
Short return visit (20+ min)	17	$781	$39
Biopsy of each additional growth of skin and/or tissue	16	$695	$22
Injection into skin growth, 1-7 growths	13	$421	$25
Short return visit	11	$203	$18

2014: 14 services

Sort by

Original Medicare services billed in 2014

Short return visit (20+ min)	207	$12,454	$43
Return visit (30+ min)	94	$8,860	$66
New patient visit (30+ min)	130	$7,811	$60
Destruction of precancer skin growth, 1 growth	101	$5,728	$43
Destruction of skin growth, 1-14 growths	58	$4,001	$60
Biopsy of single growth of skin and/or tissue	71	$2,647	$32
New patient visit (30+ min)	25	$2,114	$85
Short return visit (20+ min)	18	$1,501	$60
New patient visit (15+ min)	30	$1,188	$40
Biopsy of single growth of skin and/or tissue	13	$1,172	$78
Destruction of precancer skin growth, 2-14 growths	73	$880	$2
Biopsy of each additional growth of skin and/or tissue	19	$862	$22
Destruction of precancer skin growth, 1 growth	13	$677	$52
Short return visit	13	$334	$22

2013: 16 services

Sort by

Original Medicare services billed in 2013

Short return visit (20+ min)	129	$7,998	$42
New patient visit (30+ min)	100	$5,891	$59
New patient visit (30+ min)	43	$4,116	$96
Destruction of precancer skin growth, 1 growth	50	$3,345	$49
Destruction of skin growth, 1-14 growths	37	$2,613	$57
New patient visit (15+ min)	28	$1,876	$67
Biopsy of single growth of skin and/or tissue	50	$1,818	$34
Return visit (30+ min)	16	$1,769	$68
New patient visit (15+ min)	37	$1,573	$43
Destruction of skin growth, 1-14 growths	12	$1,286	$107
Destruction of precancer skin growth, 1 growth	17	$1,232	$62
Biopsy of single growth of skin and/or tissue	13	$1,226	$88
Short return visit (20+ min)	16	$1,107	$65
Destruction of precancer skin growth, 2-14 growths	33	$811	$4
Short return visit	19	$455	$20
Destruction of precancer skin growth, 2-14 growths	14	$411	$6

Drugs they prescribed that Part D paid

$86,768

Pharmacies billed $86,768 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 128) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

115 generic and 13 brand-name prescriptions · $86,768 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Cosentyx Sensoready (2 Pens)	11	$81,528	$7,412
Hydroxychloroquine Sulfate	12	$1,303	$109
Minoxidil	34	$800	$24
Finasteride	15	$181	$12

Year by year

Sort by

Part D prescribing by year

2024	128	31	0% (0)	10%	$86,768
2023	87	29	0% (0)	None	$135,280
2022	51	24	0% (0)	None	$23,039
2021	99	30	0% (0)	None	$96,507
2020	132	45	None	25%	$145,318
2019	218	71	0% (0)	15%	$167,906
2018	474	147	0% (0)	12%	$160,102
2017	510	130	None	14%	$142,947
2016	660	161	0% (0)	20%	$165,039
2015	662	212	None	16%	$180,812
2014	644	204	None	16%	$58,430
2013	413	134	0% (0)	None	$28,098

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 2 drugs

Sort by

Part D drugs prescribed in 2023

Minoxidil	21	$253	$12
Triamcinolone Acetonide	15	$200	$13

2021: 1 drug

Sort by

Part D drugs prescribed in 2021

Triamcinolone Acetonide	21	$238	$11

2020: 4 drugs

Sort by

Part D drugs prescribed in 2020

Fluocinonide	12	$679	$57
Finasteride	13	$325	$25
Triamcinolone Acetonide	11	$184	$17
Hydrocortisone	14	$143	$10

2019: 7 drugs

Sort by

Part D drugs prescribed in 2019

Tacrolimus	18	$2,501	$139
Fluocinonide	13	$962	$74
Clindamycin Phosphate	14	$911	$65
Triamcinolone Acetonide	40	$608	$15
Finasteride	17	$303	$18
Hydrocortisone	18	$284	$16
Gabapentin	11	$159	$14

2018: 12 drugs

Sort by

Part D drugs prescribed in 2018

Cosentyx Pen (2 Pens)	12	$60,055	$5,005
Clobetasol Propionate	38	$4,095	$108
Tacrolimus	16	$2,751	$172
Fluocinonide	44	$2,439	$55
Desonide	16	$2,006	$125
Fluorouracil	15	$1,870	$125
Clindamycin Phosphate	23	$1,587	$69
Ketoconazole	41	$961	$23
Triamcinolone Acetonide	67	$840	$13
Hydrocortisone	29	$229	$8
Finasteride	25	$201	$8
Hydroxyzine	23	$175	$8

2017: 16 drugs

Sort by

Part D drugs prescribed in 2017

Cosentyx Pen (2 Pens)	14	$64,022	$4,573
Clobetasol Propionate	42	$9,538	$227
Desonide	19	$3,518	$185
Fluorouracil	23	$3,403	$148
Tacrolimus	17	$3,344	$197
Fluocinonide	34	$3,144	$92
Calcipotriene	13	$2,799	$215
Clindamycin Phosphate	17	$1,773	$104
Dapsone	12	$1,236	$103
Triamcinolone Acetonide	76	$1,075	$14
Methotrexate	25	$849	$34
Ketoconazole	37	$707	$19
Hydroxyzine	22	$350	$16
Finasteride	22	$338	$15
Valacyclovir	11	$238	$22
Hydrocortisone	23	$160	$7

2016: 16 drugs

Sort by

Part D drugs prescribed in 2016

Clobetasol Propionate	78	$16,647	$213
Desonide	35	$5,904	$169
Tacrolimus	11	$3,385	$308
Fluocinonide	33	$2,949	$89
Fluorouracil	23	$2,309	$100
Clindamycin Phosphate	22	$1,836	$83
Triamcinolone Acetonide	84	$1,828	$22
Methotrexate	30	$1,565	$52
Doxycycline Hyclate	12	$1,503	$125
Ketoconazole	55	$1,261	$23
Econazole Nitrate	12	$1,140	$95
Valacyclovir	18	$455	$25
Levocetirizine Dihydrochloride	14	$419	$30
Finasteride	31	$405	$13
Hydrocortisone	22	$193	$9
Hydroxyzine	17	$184	$11

2015: 16 drugs

Sort by

Part D drugs prescribed in 2015

Clobetasol Propionate	75	$17,860	$238
Acitretin	13	$8,165	$628
Desonide	46	$5,996	$130
Clindamycin Phosphate	46	$3,616	$79
Fluocinonide	38	$3,406	$90
Triamcinolone Acetonide	119	$2,995	$25
Fluorouracil	13	$2,066	$159
Doxycycline Hyclate	13	$1,861	$143
Methotrexate	18	$1,632	$91
Imiquimod	11	$1,569	$143
Mycophenolate Mofetil	20	$977	$49
Ketoconazole	40	$976	$24
Minocycline	12	$527	$44
Levocetirizine Dihydrochloride	13	$496	$38
Doxepin	19	$390	$21
Hydroxyzine	15	$260	$17

2014: 13 drugs

Sort by

Part D drugs prescribed in 2014

Clobetasol Propionate	112	$10,223	$91
Desonide	34	$7,219	$212
Triamcinolone Acetonide	124	$3,112	$25
Doxycycline Hyclate	19	$2,367	$125
Tretinoin	12	$2,197	$183
Fluorouracil	11	$2,091	$190
Fluocinonide	20	$1,778	$89
Clindamycin Phosphate	27	$1,492	$55
Ketoconazole	61	$1,184	$19
Econazole Nitrate	28	$1,154	$41
Methotrexate	14	$448	$32
Terbinafine	11	$154	$14
Doxepin	14	$138	$10

2013: 10 drugs

Sort by

Part D drugs prescribed in 2013

Desonide	14	$3,682	$263
Doxycycline Hyclate	30	$3,659	$122
Clindamycin Phosphate	41	$2,616	$64
Clobetasol Propionate	71	$1,987	$28
Fluocinonide	18	$1,474	$82
Tretinoin	14	$1,467	$105
Triamcinolone Acetonide	45	$1,073	$24
Econazole Nitrate	19	$1,072	$56
Ketoconazole	45	$926	$21
Hydroxyzine	13	$301	$23

Money from drug and device companies

$15,514 in 2025

Sort by

Industry payments by year

2025	3	13	$15,192	$15,514
2024	5	29	$50,782	$55,730
2023	5	54	$49,750	$65,474
2022	3	18	$28,250	$29,435
2021	2	6	$22,025	$22,025
2020	2	5	$46,224	$46,224
2019	3	8	$833	$2,637

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Abbvie	Rinvoq	$11,793	10 payments Meals for Skyrizi · 2025-12-18 · $10 Consulting for Rinvoq · 2025-11-14 · $2,600 Consulting for Rinvoq · 2025-11-14 · $3,900 Travel for Rinvoq · 2025-11-14 · $48 Meals for Rinvoq · 2025-11-14 · $68 Travel for Rinvoq · 2025-11-14 · $76 Consulting for Rinvoq · 2025-10-22 · $704 Consulting for Rinvoq · 2025-08-14 · $650 Consulting for Rinvoq · 2025-07-01 · $2,600 Consulting for Skyrizi · 2025-06-26 · $1,138
Eli Lilly and	Olumiant	$3,600	2 payments Consulting for Olumiant · 2025-03-21 · $2,800 Consulting for Olumiant · 2025-03-21 · $800
Genzyme	None	$121	1 payment Meals · 2025-02-06 · $121

See all 13 published payments

Sort by

Every published payment

Abbvie	Meals · 2025-12-18	Skyrizi	$10
Abbvie	Consulting · 2025-11-14	Rinvoq	$2,600
Abbvie	Consulting · 2025-11-14	Rinvoq	$3,900
Abbvie	Travel · 2025-11-14	Rinvoq	$48
Abbvie	Meals · 2025-11-14	Rinvoq	$68
Abbvie	Travel · 2025-11-14	Rinvoq	$76
Abbvie	Consulting · 2025-10-22	Rinvoq	$704
Abbvie	Consulting · 2025-08-14	Rinvoq	$650
Abbvie	Consulting · 2025-07-01	Rinvoq	$2,600
Abbvie	Consulting · 2025-06-26	Skyrizi	$1,138
Eli Lilly and	Consulting · 2025-03-21	Olumiant	$2,800
Eli Lilly and	Consulting · 2025-03-21	Olumiant	$800
Genzyme	Meals · 2025-02-06	None	$121

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $55,730

Sort by

Payments by company in 2024

Genzyme	None	$31,155	16 payments Meals · 2024-11-08 · $136 Travel · 2024-11-08 · $259 Travel · 2024-11-08 · $491 Travel · 2024-11-08 · $99 Consulting · 2024-11-08 · $11,956 Travel · 2024-11-08 · $263 Meals · 2024-04-19 · $100 Meals · 2024-04-19 · $57 Meals · 2024-04-19 · $55 Meals · 2024-04-19 · $59 Consulting · 2024-04-19 · $16,226 Meals · 2024-04-19 · $60 Travel · 2024-04-19 · $143 Travel · 2024-04-19 · $797 Travel · 2024-04-19 · $290 Travel · 2024-04-19 · $166
Pfizer	Cibinqo	$15,427	8 payments Meals for Cibinqo · 2024-12-03 · $6 Paid to speak or teach for Litfulo · 2024-11-04 · $3,850 Paid to speak or teach for Cibinqo · 2024-06-24 · $2,250 Paid to speak or teach for Cibinqo · 2024-06-12 · $7,500 Travel for Cibinqo · 2024-05-17 · $640 Travel for Cibinqo · 2024-05-17 · $514 Travel for Cibinqo · 2024-05-17 · $450 Meals for Cibinqo · 2024-05-17 · $216
Abbvie	None	$5,518	3 payments Consulting · 2024-04-16 · $5,400 Meals · 2024-04-16 · $20 Travel · 2024-04-16 · $98
Lilly USA	Olumiant	$3,600	1 payment Consulting for Olumiant · 2024-07-12 · $3,600
E.R. Squibb & Sons L.L.C.	Sotyktu	$30	1 payment Meals for Sotyktu · 2024-03-08 · $30

2023: $65,474

Sort by

Payments by company in 2023

Eli Lilly and	Olumiant	$35,311	11 payments Paid to speak or teach · 2023-11-27 · $5,600 Consulting · 2023-09-25 · $11,200 Travel · 2023-09-15 · $371 Travel · 2023-09-15 · $337 Travel · 2023-09-15 · $263 Travel · 2023-09-15 · $298 Travel · 2023-07-06 · $7,578 Travel · 2023-07-06 · $92 Travel · 2023-07-06 · $92 Consulting · 2023-06-06 · $9,400 Meals for Olumiant · 2023-03-16 · $80
Pfizer	Cibinqo	$21,389	13 payments Paid to speak or teach for Cibinqo · 2023-10-20 · $3,000 Travel for Cibinqo · 2023-07-14 · $188 Paid to speak or teach for Cibinqo · 2023-06-13 · $8,800 Paid to speak or teach for Litfulo · 2023-06-05 · $2,750 Travel for Eucrisa · 2023-05-12 · $601 Travel for Eucrisa · 2023-05-12 · $442 Meals for Eucrisa · 2023-05-12 · $231 Travel for Eucrisa · 2023-05-12 · $325 Education for Cibinqo · 2023-04-12 · $15 Paid to speak or teach · 2023-02-14 · $3,400 Travel for Litfulo · 2023-01-26 · $336 Meals for Litfulo · 2023-01-26 · $67 Travel for Litfulo · 2023-01-26 · $1,233
Lilly USA	Olumiant	$7,569	22 payments Consulting · 2023-07-12 · $3,200 Meals for Olumiant · 2023-06-05 · $35 Travel for Olumiant · 2023-06-05 · $27 Meals for Olumiant · 2023-06-05 · $31 Meals for Olumiant · 2023-06-05 · $10 Travel for Olumiant · 2023-06-05 · $5 Paid to speak or teach for Olumiant · 2023-02-16 · $2,400 Travel · 2023-02-01 · $117 Travel · 2023-02-01 · $184 Travel · 2023-02-01 · $161 Meals · 2023-02-01 · $25 Travel · 2023-02-01 · $161 Education · 2023-02-01 · $50 Meals · 2023-02-01 · $45 Travel · 2023-02-01 · $263 Meals · 2023-02-01 · $60 Travel · 2023-02-01 · $263 Meals · 2023-02-01 · $50 Meals · 2023-02-01 · $140 Meals · 2023-02-01 · $78 Meals · 2023-02-01 · $104 Travel · 2023-02-01 · $161
Abbvie	Rinvoq	$1,180	7 payments Meals for Rinvoq · 2023-11-11 · $60 Meals for Rinvoq · 2023-11-11 · $25 Meals for Rinvoq · 2023-11-11 · $25 Meals for Rinvoq · 2023-11-11 · $70 Travel for Rinvoq · 2023-11-10 · $447 Travel for Rinvoq · 2023-11-10 · $278 Travel for Rinvoq · 2023-11-10 · $275
LEO Pharma	None	$25	1 payment Education · 2023-11-06 · $25

2022: $29,435

Sort by

Payments by company in 2022

Eli Lilly and	None	$14,920	11 payments Consulting · 2022-12-23 · $4,800 Consulting · 2022-12-20 · $1,600 Consulting · 2022-04-04 · $800 Consulting · 2022-03-29 · $4,000 Meals · 2022-03-24 · $97 Meals · 2022-03-24 · $45 Meals · 2022-03-24 · $33 Meals · 2022-03-24 · $18 Meals · 2022-03-24 · $52 Meals · 2022-03-24 · $24 Paid to speak or teach · 2022-01-21 · $3,450
Pfizer	Cibinqo	$11,515	6 payments Consulting for Cibinqo · 2022-12-12 · $3,000 Travel · 2022-07-21 · $124 Paid to speak or teach · 2022-06-20 · $4,000 Travel · 2022-06-04 · $429 Travel · 2022-06-04 · $361 Honoraria for Cibinqo · 2022-05-27 · $3,600
Lilly USA	None	$3,000	1 payment Consulting · 2022-11-29 · $3,000

2021: $22,025

Sort by

Payments by company in 2021

Pfizer	None	$11,100	3 payments Paid to speak or teach · 2021-11-05 · $3,000 Honoraria · 2021-10-22 · $5,100 Honoraria · 2021-07-12 · $3,000
Eli Lilly and	None	$10,925	3 payments Consulting · 2021-06-28 · $3,738 Consulting · 2021-05-05 · $4,888 Paid to speak or teach · 2021-01-21 · $2,300

2020: $46,224

Sort by

Payments by company in 2020

LEO Pharma AS	None	$32,336	1 payment Consulting · 2020-01-02 · $32,336
Eli Lilly and	None	$13,888	4 payments Consulting · 2020-12-11 · $2,588 Consulting · 2020-08-06 · $4,600 Consulting · 2020-06-16 · $2,100 Consulting · 2020-05-04 · $4,600

2019: $2,637

Sort by

Payments by company in 2019

LEO Pharma AS	None	$1,789	6 payments Travel · 2019-10-14 · $67 Travel · 2019-09-09 · $229 Travel · 2019-09-09 · $383 Meals · 2019-09-09 · $14 Travel · 2019-04-02 · $576 Travel · 2019-04-02 · $520
Allergan	None	$833	1 payment Paid to speak or teach · 2019-12-12 · $833
AbbVie	Skyrizi	$15	1 payment Education for Skyrizi · 2019-07-10 · $15

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata · 2019	Their institution	$169,936
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata · 2020	Their institution	$166,753
ARENA PHARMACEUTICALS, INC. · A Multicenter Randomized Doubleblind Placebocontrolled 24week Study With A 28week Openlabel Extension To Assess the Safety and Efficacy of Etrasimod in Subjects With Moderatetosevere Alopecia Areata · 2022	Their institution	$66,922
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata · 2021	Their institution	$59,179
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata · 2022	Their institution	$44,826
ARENA PHARMACEUTICALS, INC. · A Multicenter Randomized Doubleblind Placebocontrolled 24week Study With A 28week Openlabel Extension To Assess the Safety and Efficacy of Etrasimod in Subjects With Moderatetosevere Alopecia Areata · 2023	Their institution	$38,819
Aclaris Therapeutics, Inc. · Randomized, Double-Blind, Vehicle-Controlled Multicenter Study To Evaluate the Safety, Tolerability and Efficacy of Ati-502 Topical Solution Administered Twice-Daily for 6 Months in Adult Subjects With Stable Patchy Alopecia Areata · 2019	Their institution	$38,270
Eli Lilly and Company · A Multicenter Randomized Double-Blind Placebo-Controlled Operationally Seamless Adaptive Phase 2/3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata · 2023	Their institution	$37,750
SANOFI US SERVICES INC. · A Phase 2, Randomized, Double-Blind, Placebo--Controlled, Parallel Group, 3-Arm, Multinational, Multicenter, Proof-of-Concept Study To Evaluate the Efficacy and Safety of Amlitelimab Monotherapy By Subcutaneous Injection in Adult Participants With Severe Alopecia Areata · 2025	Their institution	$35,699
SUN PHARMACEUTICAL INDUSTRIES INC. · Extension Study To Evaluate Safety and Efficacy of Ctp-543 in Adults With Alopecia Areata · 2024	Their institution	$30,376
ABBVIE INC. · A Study To Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-Aa) · 2024	Their institution	$24,100
PFIZER INC. · Presto Characterization and Clinical Outcomes of Alopecia Aerata Aa Patients Treated With Ritlecitinib in A Realworld Rw Cohort A Multinational Prospective Observational Study · 2025	Their institution	$21,107
ABBVIE INC. · A Study To Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-Aa) · 2025	Their institution	$13,875
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata · 2025	Their institution	$11,900
ABBVIE INC. · M23-716 Rinvoq Ph 3 Alopecia Areata · 2024	Their institution	$9,223
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata · 2024	Their institution	$7,367
SUN PHARMACEUTICAL INDUSTRIES INC. · Extension Study To Evaluate Safety and Efficacy of Ctp-543 in Adults With Alopecia Areata · 2023	Their institution	$7,340
PFIZER INC. · Ritlecitinib Clinical Publication Program · 2023	This clinician	$3,200
ABBVIE INC. · Multicenter, Evaluator-Blinded, Randomized, Controlled Study of the Safety and Effectiveness of Juvederm Volite Xc Injectable Gel for Improvement in Neck Appearance · 2025	Their institution	$1,780
ABBVIE INC. · A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program To Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata · 2025	Their institution	$1,402
PFIZER INC. · Ritlecitinib Clinical Publication Program · 2022	This clinician	$1,270
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata · 2022	This clinician	$487
PFIZER INC. · Ritlecitinib Clinical Publication Program · 2025	This clinician	$330
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata · 2020	This clinician	$18

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1790912251
Licence: CA A120641, MA L-239279California A120641: Current · expires 2027-07-31
Trained: Tufts University School of Medicine, 2008
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Taxonomy: Federal specialty code 207N00000X (207N00000X)
Mailing address: 440 Broadway St Fl B4, Redwood City, CA, 94063
NPI first listed: 2009-06-11
NPI last updated: 2024-04-16
NPI record certified: 2024-04-16

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 440 Broadway St Fl B4, Redwood City, CA, 94063